Olufunmilayo Olopade to Mutation
This is a "connection" page, showing publications Olufunmilayo Olopade has written about Mutation.
Connection Strength
5.432
-
Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report. Clin Breast Cancer. 2015 Apr; 15(2):e155-8.
Score: 0.228
-
Genetic determinants of breast cancer risk: a review of current literature and issues pertaining to clinical application. Breast J. 2012 Sep; 18(5):436-42.
Score: 0.198
-
Hidden dangers: a cryptic exon disrupts BRCA2 mRNA. Clin Cancer Res. 2012 Sep 15; 18(18):4865-7.
Score: 0.197
-
High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. Int J Cancer. 2012 Sep 01; 131(5):1114-23.
Score: 0.190
-
Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer. Breast Cancer Res Treat. 2010 Dec; 124(3):857-61.
Score: 0.171
-
Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States. J Clin Oncol. 2009 Mar 10; 27(8):1184-90.
Score: 0.154
-
Evidence for an ancient BRCA1 mutation in breast cancer patients of Yoruban ancestry. Fam Cancer. 2009; 8(1):15-22.
Score: 0.149
-
Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet Med. 2008 Mar; 10(3):161-166.
Score: 0.145
-
BRCA2 mutation and the risk of hematologic malignancy. Leuk Lymphoma. 2006 Apr; 47(4):765-7.
Score: 0.127
-
Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations. Breast Cancer Res. 2023 05 25; 25(1):58.
Score: 0.104
-
Mutational spectrum of breast cancer susceptibility genes among women ascertained in a cancer risk clinic in Northeast Brazil. Breast Cancer Res Treat. 2022 Jun; 193(2):485-494.
Score: 0.096
-
Cancer genetics in oncology practice. Ann Oncol. 2001 Jul; 12(7):895-908.
Score: 0.091
-
Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001 Jun 28; 344(26):2028-9.
Score: 0.091
-
Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer. Hum Genet. 2000 Aug; 107(2):186-91.
Score: 0.085
-
Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Res. 2020 02 01; 80(3):624-638.
Score: 0.081
-
USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan. JAMA Netw Open. 2019 08 02; 2(8):e1910142.
Score: 0.080
-
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2019 07; 121(2):180-192.
Score: 0.079
-
Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. J Natl Cancer Inst. 2019 04 01; 111(4):350-364.
Score: 0.078
-
Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. Br J Cancer. 2019 02; 120(4):398-403.
Score: 0.077
-
Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. Nat Commun. 2018 10 16; 9(1):4181.
Score: 0.075
-
Mutations in context: implications of BRCA testing in diverse populations. Fam Cancer. 2018 10; 17(4):471-483.
Score: 0.075
-
Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers. Clin Cancer Res. 2019 03 15; 25(6):1786-1794.
Score: 0.075
-
Inherited Breast Cancer in Nigerian Women. J Clin Oncol. 2018 10 01; 36(28):2820-2825.
Score: 0.075
-
Predisposition testing for inherited breast cancer. Oncology (Williston Park). 1998 Aug; 12(8):1227-41; discussion 1241-2.
Score: 0.074
-
Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat. 2018 05; 39(5):593-620.
Score: 0.072
-
Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2018 Jun; 169(3):561-571.
Score: 0.072
-
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet. 2017 Dec; 49(12):1767-1778.
Score: 0.071
-
Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2017 07 01; 109(7).
Score: 0.069
-
Recurrent germ-line BRCA1 mutations in extended African American families with early-onset breast cancer. Am J Hum Genet. 1997 May; 60(5):1233-6.
Score: 0.068
-
Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J Clin Oncol. 2017 Jul 10; 35(20):2240-2250.
Score: 0.068
-
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Res Treat. 2017 01; 161(1):117-134.
Score: 0.066
-
Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2. Breast Cancer Res Treat. 2016 11; 160(1):121-129.
Score: 0.065
-
Mutation spectrum and risk of colorectal cancer in African American families with Lynch syndrome. Gastroenterology. 2015 Nov; 149(6):1446-53.
Score: 0.060
-
An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res. 2015 Apr 25; 17:61.
Score: 0.059
-
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015 Apr 07; 313(13):1347-61.
Score: 0.059
-
Inherited predisposition to breast cancer among African American women. Breast Cancer Res Treat. 2015 Jan; 149(1):31-9.
Score: 0.058
-
Relationships between computer-extracted mammographic texture pattern features and BRCA1/2 mutation status: a cross-sectional study. Breast Cancer Res. 2014; 16(4):424.
Score: 0.057
-
Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014 Jul; 146(2):421-7.
Score: 0.056
-
The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation. Breast Cancer Res Treat. 2013 Nov; 142(1):177-85.
Score: 0.053
-
Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? Breast Cancer Res Treat. 2013 Feb; 138(1):273-9.
Score: 0.051
-
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2011; 13(6):R110.
Score: 0.047
-
Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nat Med. 2011 Jul 24; 17(8):941-3.
Score: 0.046
-
Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2011 Apr 26; 104(9):1384-92.
Score: 0.045
-
Is screening with magnetic resonance imaging in BRCA mutation carriers a safe and effective alternative to prophylactic mastectomy? J Clin Oncol. 2011 May 01; 29(13):1652-4.
Score: 0.045
-
Germline mutational analysis of the C19orf62 gene in African-American women with breast cancer. Breast Cancer Res Treat. 2011 Jun; 127(3):871-7.
Score: 0.045
-
Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2011 May; 127(1):287-96.
Score: 0.044
-
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res. 2010 Dec 01; 70(23):9742-54.
Score: 0.044
-
Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat. 2010 Nov; 124(1):195-203.
Score: 0.041
-
Risk assessment and genetic testing for ovarian cancer. AJR Am J Roentgenol. 2010 Feb; 194(2):309-10.
Score: 0.041
-
Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Cancer Res. 2009 Jul 15; 69(14):5801-10.
Score: 0.040
-
Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer. 2008 Jul 22; 99(2):371-4.
Score: 0.037
-
Should genetic testing for BRCA1/2 be permitted for minors? Opinions of BRCA mutation carriers and their adult offspring. Am J Med Genet C Semin Med Genet. 2008 Feb 15; 148C(1):70-7.
Score: 0.036
-
Genetic testing in diverse populations: are researchers doing enough to get out the correct message? JAMA. 2007 Dec 26; 298(24):2910-1.
Score: 0.036
-
Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer. 2007 Dec 15; 121(12):2661-7.
Score: 0.036
-
How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults. J Clin Oncol. 2007 Aug 20; 25(24):3705-11.
Score: 0.035
-
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006 Jun 01; 24(16):2437-43.
Score: 0.032
-
Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res. 2006; 8(2):R15.
Score: 0.032
-
Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer. 2005 Dec 20; 117(6):988-91.
Score: 0.031
-
Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA. 2005 Oct 19; 294(15):1925-33.
Score: 0.031
-
Breast cancer and race: a rising tide does not lift all boats equally. Perspect Biol Med. 2005; 48(1 Suppl):S166-75.
Score: 0.029
-
Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a BRCA1 or BRCA2 Mutation. Cancer Res Commun. 2023 11 28; 3(11):2420-2429.
Score: 0.027
-
Direct-to-consumer marketing of genetic tests for cancer: buyer beware. J Clin Oncol. 2003 Sep 01; 21(17):3191-3.
Score: 0.026
-
Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation. Breast Cancer Res Treat. 2023 Sep; 201(2):257-264.
Score: 0.026
-
Breast cancer genetics in African Americans. Cancer. 2003 Jan 01; 97(1 Suppl):236-45.
Score: 0.025
-
The risks of cancer in older women with BRCA pathogenic variants: How far have we come? Cancer. 2023 03 15; 129(6):901-907.
Score: 0.025
-
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2002 Dec 04; 94(23):1773-9.
Score: 0.025
-
Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal. Cancer Epidemiol Biomarkers Prev. 2022 07 01; 31(7):1351-1358.
Score: 0.024
-
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst. 2002 Jun 05; 94(11):844-51.
Score: 0.024
-
Differences in somatic TP53 mutation type in breast tumors by race and receptor status. Breast Cancer Res Treat. 2022 Apr; 192(3):639-648.
Score: 0.024
-
Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center. Ann Surg Oncol. 2022 Feb; 29(2):1423-1432.
Score: 0.023
-
Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiol Biomarkers Prev. 2021 11; 30(11):2038-2043.
Score: 0.023
-
The impact of site-specific digital histology signatures on deep learning model accuracy and bias. Nat Commun. 2021 07 20; 12(1):4423.
Score: 0.023
-
Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet. 2001 Mar; 38(3):159-64.
Score: 0.022
-
A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nat Commun. 2021 02 17; 12(1):1078.
Score: 0.022
-
Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol. 2020 12; 159(3):820-826.
Score: 0.022
-
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genet Med. 2020 10; 22(10):1653-1666.
Score: 0.021
-
Evidence of a founder BRCA1 mutation in Scotland. Br J Cancer. 2000 Feb; 82(3):705-11.
Score: 0.021
-
Computerized analysis of mammographic parenchymal patterns for breast cancer risk assessment: feature selection. Med Phys. 2000 Jan; 27(1):4-12.
Score: 0.021
-
Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response. Cell Death Dis. 2019 09 11; 10(9):666.
Score: 0.020
-
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999 Sep 01; 91(17):1475-9.
Score: 0.020
-
BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. Hum Mutat. 2019 10; 40(10):1781-1796.
Score: 0.020
-
Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2019 Jun; 175(2):443-449.
Score: 0.019
-
Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst. 1998 May 20; 90(10):761-6.
Score: 0.018
-
Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. JAMA Oncol. 2017 12 01; 3(12):1654-1662.
Score: 0.018
-
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017 May; 49(5):680-691.
Score: 0.017
-
Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention. Cancer Prev Res (Phila). 2017 Apr; 10(4):255-266.
Score: 0.017
-
Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res. 2016 06 21; 18(1):64.
Score: 0.016
-
Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nat Commun. 2016 04 27; 7:11375.
Score: 0.016
-
Naturally occurring BRCA2 alternative mRNA splicing events in clinically relevant samples. J Med Genet. 2016 08; 53(8):548-58.
Score: 0.016
-
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2016 Feb 09; 18(1):15.
Score: 0.016
-
Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet. 2015 Feb; 47(2):164-71.
Score: 0.015
-
Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2015 Jan; 24(1):308-16.
Score: 0.014
-
MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency. Tumour Biol. 2013 Dec; 34(6):3945-58.
Score: 0.013
-
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 2013; 9(3):e1003212.
Score: 0.013
-
Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Mol Oncol. 2013 Jun; 7(3):359-68.
Score: 0.013
-
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2012 Aug; 21(8):1362-70.
Score: 0.012
-
Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Res. 2011 Sep 01; 71(17):5792-805.
Score: 0.011
-
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011 Jul 01; 12(1):9-46.
Score: 0.011
-
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010 Sep 01; 304(9):967-75.
Score: 0.011
-
Parent opinions regarding the genetic testing of minors for BRCA1/2. J Clin Oncol. 2010 Jul 20; 28(21):3498-505.
Score: 0.011
-
RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. Cancer Res. 2008 Jan 01; 68(1):22-5.
Score: 0.009
-
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet. 2007 Dec; 81(6):1186-200.
Score: 0.009
-
Fractal analysis of mammographic parenchymal patterns in breast cancer risk assessment. Acad Radiol. 2007 May; 14(5):513-21.
Score: 0.009
-
The I1307K APC polymorphism in Ashkenazi Jews with colorectal cancer: clinical and pathologic features. Cancer Genet Cytogenet. 2006 Aug; 169(1):33-8.
Score: 0.008
-
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006 Jul 12; 296(2):185-92.
Score: 0.008
-
Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control. 2005 Aug; 16(6):667-74.
Score: 0.008
-
Computerized texture analysis of mammographic parenchymal patterns of digitized mammograms. Acad Radiol. 2005 Jul; 12(7):863-73.
Score: 0.008
-
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004 Jun 15; 22(12):2328-35.
Score: 0.007
-
Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res. 2004 Mar 15; 10(6):2029-34.
Score: 0.007
-
Computerized analysis of mammographic parenchymal patterns for assessing breast cancer risk: effect of ROI size and location. Med Phys. 2004 Mar; 31(3):549-55.
Score: 0.007
-
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004 Mar 15; 22(6):1055-62.
Score: 0.007
-
MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res. 2004 Jan 15; 10(2):499-507.
Score: 0.007
-
Lack of evidence for a polymorphism at codon 160 of human O6-alkylguanine-DNA alkyltransferase gene in normal tissue and cancer. Clin Cancer Res. 1999 Jan; 5(1):209-13.
Score: 0.005
-
p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 1994 Nov 01; 54(21):5547-51.
Score: 0.004